Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
Public ClinicalTrials.gov record NCT02096263. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Immunogenicity and Safety Study of GSK Biologicals' Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age.
Study identification
- NCT ID
- NCT02096263
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 585 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Weeks to 12 Weeks
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 16, 2014 (Actual)
- Primary completion
- Feb 6, 2015 (Actual)
- Completion
- Nov 13, 2015 (Actual)
- Last update posted
- Nov 27, 2019
2014 – 2015
United States locations
- U.S. sites
- 43
- U.S. states
- 18
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Tucson | Arizona | 85741 | — |
| GSK Investigational Site | Fayetteville | Arkansas | 72703 | — |
| GSK Investigational Site | Anaheim | California | 92804 | — |
| GSK Investigational Site | Daly City | California | 94015 | — |
| GSK Investigational Site | Fresno | California | 93726 | — |
| GSK Investigational Site | Hayward | California | 94545 | — |
| GSK Investigational Site | Oakland | California | 94611 | — |
| GSK Investigational Site | Pleasanton | California | 94588 | — |
| GSK Investigational Site | Roseville | California | 95661 | — |
| GSK Investigational Site | Sacramento | California | 95815 | — |
| GSK Investigational Site | Sacramento | California | 95823 | — |
| GSK Investigational Site | San Jose | California | 95119 | — |
| GSK Investigational Site | Santa Clara | California | 95051 | — |
| GSK Investigational Site | Walnut Creek | California | 94596 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80922 | — |
| GSK Investigational Site | Altamonte Springs | Florida | 32701 | — |
| GSK Investigational Site | Orange City | Florida | 32763 | — |
| GSK Investigational Site | Marietta | Georgia | 30062 | — |
| GSK Investigational Site | Woodstock | Georgia | 30189 | — |
| GSK Investigational Site | Nampa | Idaho | 83686 | — |
| GSK Investigational Site | Augusta | Kansas | 67010 | — |
| GSK Investigational Site | Newton | Kansas | 67114 | — |
| GSK Investigational Site | Topeka | Kansas | 66604 | — |
| GSK Investigational Site | Wichita | Kansas | 67205 | — |
| GSK Investigational Site | Louisville | Kentucky | 40202 | — |
| GSK Investigational Site | Louisville | Kentucky | 40291 | — |
| GSK Investigational Site | Nicholasville | Kentucky | 40356 | — |
| GSK Investigational Site | Columbia | Maryland | 21045 | — |
| GSK Investigational Site | Kansas City | Missouri | 64108 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | Dayton | Ohio | 45414 | — |
| GSK Investigational Site | Erie | Pennsylvania | 16505 | — |
| GSK Investigational Site | Sellersville | Pennsylvania | 18960 | — |
| GSK Investigational Site | Kingsport | Tennessee | 37660 | — |
| GSK Investigational Site | Layton | Utah | 84041 | — |
| GSK Investigational Site | Payson | Utah | 84651 | — |
| GSK Investigational Site | Provo | Utah | 84604 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84109 | — |
| GSK Investigational Site | South Jordan | Utah | 84095 | — |
| GSK Investigational Site | St. George | Utah | 84790 | — |
| GSK Investigational Site | West Jordan | Utah | 84088 | — |
| GSK Investigational Site | Charlottesville | Virginia | 22902 | — |
| GSK Investigational Site | Ellensburg | Washington | 98926 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02096263, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 27, 2019 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02096263 live on ClinicalTrials.gov.